Data Readout

Dogwood's Halneuron heads toward Phase 2b pain data with no direct rival

The randomized, placebo-controlled trial testing Halneuron in chemotherapy nerve pain is still recruiting toward a mid-2026 completion, with final 200-patient data expected in the second half of the year.

By AppliedXLJuly 13, 2026Trial NCT06848348

Executive Summary

Dogwood Therapeutics is running toward the final readout of its randomized, placebo-controlled Phase 2b trial of Halneuron in chemotherapy-induced neuropathic pain, with the full dataset expected in the second half of 2026.
Halneuron targets a sodium-channel mechanism with no approved or late-stage precedent in this specific pain population, so the trial will be the first randomized human test of whether this approach beats placebo where existing oral therapies have fallen short.
The trial's recent enrollment increase and stable protocol history point to routine execution rather than distress, shifting the open question toward the result itself rather than whether the study will complete.
Fast Track designation from the FDA reflects recognized unmet need in this pain population but carries no bearing on whether the trial will show a benefit.

The trial

The study, registered as NCT06848348, is randomizing adults with neuropathic pain attributed to prior platinum or taxane chemotherapy to Halneuron or placebo, delivered subcutaneously. It carries two primary endpoints exploring safety and efficacy, measured on an NRS pain scale, alongside four secondary endpoints covering sleep quality, fatigue, mood and patient global impression of change. The trial is Recruiting, with a primary completion date of July 1, 2026, and enrollment lifted from 200 to 240 patients as of May 29, 2026. NCT06848348

Probability of Success

Endpoint Met26%

Completes82%

Clinical Significance21%

Regulatory62%

What Dogwood has said

Dogwood's chief executive, Greg Duncan, said in November 2025 that the company had enrolled 100 patients and completed treatment in 80, with an interim analysis expected in the fourth quarter of 2025 and final data on the full 200-patient dataset expected in the second half of 2026. The company's guided window for that final readout has since moved between quarterly and half-year framing across six separate updates from November 2025 through May 2026, most recently settling back on a second-half 2026 window that runs through December 31. Dogwood

The mechanism and the field

Halneuron is described as a non-opioid NaV 1.7 sodium-channel modulator, a class the company has framed as effective at blocking pain transmission. No other industry trial pairs this target with chemotherapy-induced neuropathic pain, and the closest indication-level comparators, including pregabalin, capsaicin and cannabidiol programs in neuropathic pain and fibromyalgia, work through unrelated mechanisms such as calcium-channel or TRPV1 modulation rather than NaV 1.7 blockade. That leaves the trial without a same-mechanism precedent to benchmark against; the informative outcome is whether a NaV 1.7-selective approach can separate from placebo in a population where existing oral neuropathic-pain drugs carry incomplete relief and tolerability trade-offs. Dogwood

Regulatory and operational context

The FDA granted Halneuron Fast Track designation for chemotherapy-induced neuropathic pain, a status the company has referenced repeatedly since November 2024. The trial's enrollment increase from 200 to 240 patients falls within the routine band the operational model uses to flag jumps, and the registry shows only one enrollment change and one status change since the study opened in February 2025, consistent with a stable protocol history. Dogwood+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.